The current study compares the results of irradiation with protons and irradiation with carbon ions via a raster scan technique in patients with G1 and G2 skull base chondrosarcomas. METHODS: Between 2009 and 2014, a total of 101 patients (40 men and 61 women) with a median age of 44 years (range, 19-77 years) were irradiated with carbon ions (79 patients) or protons (22 patients) via a raster scan technique at the Heidelberg Ion Beam Therapy Center. The median total dose was 60 Gy (relative biological effectiveness [RBE]) at 3 Gy per fraction for carbon ions and 70 Gy (RBE) at 2 Gy per fraction for protons. The median boost planning target volume was 38 cm 3 (range, 8-133 cm 3 ). Overall survival (OS) and local control (LC) were evaluated with the Kaplan-Meier method. RESULTS: The median follow-up period was 40 months (range, 0.8-78.1 months). At the start of the irradiation, all patients had residual macroscopic tumors. Five patients (5%) developed a local recurrence during the follow-up. The 1-, 2-, and 4-year LC rates were 100%, 100%, and 100%, respectively, for protons and 98.6%, 97.2%, and 90.5%, respectively, for carbon ions. The OS rates during the same periods of time were 100%, 100%, and 100%, respectively, for protons and 100%, 98.5%, and 92.9%, respectively, for carbon ions. An age 44 years was associated with a trend for a better outcome. No toxicity worse than Common Toxicity Criteria grade 3 was observed after treatment. CONCLUSIONS: No significant difference between carbon ions and protons in the therapy of skull base chondrosarcoma could be detected in these initial retrospective results.
INTRODUCTION
Chondrosarcoma is a rare malignant tumor that most likely arises from the remaining chondrocytes of the enchondral ossification. 1 They can occur de novo or develop from benign bone tumors such as enchondromas. The risk for a malignant transformation is >10% if there are multiple benign bone tumors, as is common in Ollier disease and Maffucci syndrome. 2, 3 Localization at the skull base is described in 5% to 12% of cases with an average age at first diagnosis of 40 years. 4 Because metastatic diseases are very rare in patients with G1/G2 chondrosarcomas (Federation Nationale des Centres de Lutte Contre le Cancer), it is important that local control (LC) be achieved. Because of the surrounding structures at the skull base, a complete surgical resection is rarely possible, and even if it can be achieved, there remains a risk of recurrence. A significant reduction in the 5-year rate of local recurrence from 44% after surgery alone to 9% after a combination of surgery and adjuvant radiotherapy was demonstrated in a systematic literature review by Bloch et al. 3, 5 Furthermore, the recurrence rate after primary radiotherapy has been shown to be lower than the rate after surgery alone (19% vs 44%). 3, 5 To achieve sufficient LC, relatively high doses are needed in conventional techniques because of the radio resistance of chondrosarcomas. To achieve the best possible protection for the surrounding organs at risk, it has been demonstrated that highly conformal treatment methods such as protons are most favorable. 6 Besides these advantages, carbon ions seem to have a higher relative biological effectiveness (RBE; [3] [4] [5] in comparison with protons. 7 Long-term data collected by our department showed an excellent LC rate of 88% at 10 years when carbon ions were used in the treatment of skull base chondrosarcomas. 8 The purpose of this study was to evaluate the role of carbon ions versus protons in the treatment of skull base chondrosarcomas with an intensity-modulated active raster scan technique at the Heidelberg Ion Beam Therapy Center (HIT) in Heidelberg, Germany.
MATERIALS AND METHODS
All patients with G1 and G2 skull base chondrosarcomas (Federation Nationale des Centres de Lutte Contre le Cancer) who were treated at the HIT between 2009 and 2014 were included in the analysis. Patients who had G3 tumors or mesenchymal chondrosarcomas or were younger than 18 years were excluded. At the start of the irradiation at the HIT, patients were irradiated with carbon ions as the standard therapy. This was established on the basis of the data acquired in the preceding phase 1/2 study. The standard therapy at Heidelberg was changed to protons when the ongoing phase 3 study was established because protons are the worldwide therapy standard. Therefore, more patients in this retrospective evaluation received carbon-ion beam treatment. Nevertheless, the reimbursement of treatment costs in some countries is linked to a specific type of ion. Hence, some patients from abroad were treated with either protons or carbon ions outside the randomized trial.
Treatment Planning and Delivery
Patients with histologically proven G1 and G2 skull base chondrosarcomas were immobilized with a thermoplastic head-mask system. Computed tomography (3-mm slices) was used in all patients for the 3-dimensional treatment planning. For the exact contouring of the treatment volume and the organs at risk, a 3-dimensional image registration with T2-weighted (T2 short tau inversion recovery) and contrast-enhanced T1-weighted magnetic resonance imaging was performed. The boost clinical target volume included the gross tumor volume with a margin of 1 to 2 mm. The primary clinical target volume contained the boost clinical target volume and the preoperative spread of the tumor. Both planning target volumes (first and second) were formed with an additional safety margin of 3 mm. Treatment planning was performed with Siemens Syngo PT Planning software. The treatment was performed at the HIT with protons and carbon ions via an active raster scan method. Detailed information concerning the carbon-ion treatment and the facility has already been published. 9 The median delivered dose was 60 Gy (RBE) in 3-Gy (RBE) fraction doses for carbon ions (5-6 3 3 Gy [RBE]/wk) and 70 Gy (RBE) in 2-Gy (RBE) fraction doses for protons (5-6 3 2 Gy [RBE]/wk).
Follow-Up
After approval by the ethics committee of the University of Heidelberg, all patients were mailed a follow-up information sheet regarding the current analysis and a questionnaire concerning their tumor status and side effects. After the patients provided signed informed consent, all medical records were evaluated, and other treating physicians were contacted if necessary. The tumor status was further evaluated by an analysis of follow-up magnetic resonance imaging scans. All data were collected in the central Heidelberg Institute for Radiation Oncology research database of the authors' department as previously described. 10 
Statistical Analysis
The evaluation of the rates for LC and overall survival (OS) was performed with the Kaplan-Meier method. Age, sex, tumor volume, and irradiation in primary and recurrent situations were tested for prognostic significance with the log-rank test. Furthermore, possible differences between the proton and carbon-ion treatments were analyzed with the log-rank test. Toxicity was evaluated through an analysis of medical records and questionnaires. Because this was a retrospective analysis, most side effects could be noted only quantitatively. Thus, the follow-up was divided into 4 periods for the proton and carbon-ion groups: baseline, 0 to 1 years, 1 to 3 years, and 3 to 5 years. For all side effects, an analysis of the unadjusted and adjusted groups was performed. The unadjusted group always included all 101 patients because the side effects of the last visit were fixed and were considered at the next follow-up interval, whereas in the adjusted group, patients dropped out after their last contact. Thus, only those patients who were contacted during the specific period of time were considered. As for the symptom of double vision, a total of 30 patients with changes in the symptom and sufficient documentation could be identified. An evaluation using the Kaplan-Meier method and the logrank test to determine possible differences between the carbon-ion and proton groups was performed. As for other side effects, no statistical analysis could be performed because the documentation was not sufficient or inconclusive. 3 ). In the total sample, 88 patients were treated in a primary situation, and 13 were treated in a recurrent situation. Seventy-nine patients received carbon-ion treatment. The remaining 22 patients received proton treatment. The median follow-up for the entire group was 40 months. The median follow-up times for the proton and carbonion group were 30.7 and 43.7 months, respectively. A total of 5 patients (5%) developed a local recurrence during the follow-up period with a median time until recurrence of 29.8 months (range, 8.1-47.3 months). All those patients had received carbon-ion treatment. No metastatic disease was discovered during the follow-up. The 1-, 2-, and 4-year LC rates for carbon-ion treatment were 98.6%, 97.2%, and 90.5%, respectively. For proton therapy, the 1-, 2-, and 4-year LC rates were 100%, 100%, and 100%, respectively. The 1-, 2-, and 4-year OS rates for carbonion treatment were 100%, 98.5%, and 92.9%, respectively. For proton therapy, the rates were 100%, 100%, and 100%, respectively. No significant difference between carbon ions and protons could be found for either OS (P 5 .384; Fig. 1 ) or LC (P 5 .357; Fig. 2 ). The patient characteristics and results are summarized in Table 1 .
RESULTS

LC, OS, and Prognostic Factors
As for a possible influence of age at the beginning of treatment, a trend toward a better outcome for patients who were 44 years old or younger could be found in comparison with patients who were older than 44 years (P 5 .196 ). This was also applicable for the analysis of only those patients who were treated with carbon ions, with a trend toward a higher LC rate in patients who were 46 years old or younger (P 5 .149; Fig. 3 ). Continuing with the trend analysis, we found no statistically significant difference between patients with a clinical target volume 36.6 cm 3 and those with a clinical target volume > 36.6 cm 3 in either the whole group (P 5 .568) or the carbonion subgroup alone (P 5 .601; Fig. 4 ). In addition, no significant difference between primary and recurrent radiotherapy could be determined in the whole group (P 5 .510; Fig. 5 ). Furthermore, no differences concerning sex could be found in the whole group (P 5 .442) or in the carbon-ion group (P 5 .447; Fig. 6 ). Because there were no relapses in the proton group, no differences could be detected in that group concerning the same points of comparison in the aforementioned analysis.
Toxicity Evaluation
As mentioned previously, the follow-up for toxicity was divided into 4 periods of time for the proton and carbon-ion groups: the baseline, 0 to 1 years, 1 to 3 years, and 3 to 5 years. The number of patients in these periods were 79, 79, 67, and 47, respectively, in the carbon-ion group and 22, 22, 19, and 3, respectively, in the proton group. Alopecia, dysgeusia, xerostomia, and mucositis occurred as acute side effects in 10% to 20% of the patients within the first follow-up interval before nearly decreasing to the initial values over the course of time. Hearing deficits increased from 25% to 43% (adjusted and unadjusted) in the carbon-ion group and from 27% to 68% (adjusted and unadjusted) in the proton group during the first follow-up interval. A rather stable rate was observed in both groups during further follow-up. At the last interval, the corresponding unadjusted and adjusted rates were 34% and 40%, respectively, for the carbon-ion group and 68% and 33%, respectively, for the proton group. A continuous decrease in the rate of cranial nerve deficits was observed in both groups. The corresponding rates at the baseline were 71% for the carbon-ion group and 59% for the proton group. The corresponding rates at the last follow-up interval were 30%/19% (unadjusted/adjusted) for the carbon-ion group and 63%/33% (unadjusted/ adjusted) for the proton group. The most common cerebral nerve paralysis affected the abducent nerve with initial rates of 35% for carbon ions and 27% for protons. A relative decrease was seen for this symptom with corresponding rates of 11%/9% (unadjusted/adjusted) for carbon ions and 14%/0% (unadjusted/adjusted) for protons at the last follow-up interval. The evaluated results also show that the symptom of double vision decreased over the course of time from 42% in the carbon-ion group to 23%/21% (unadjusted/adjusted). Stable numbers were found for the proton group with 32% at the baseline and 36%/33% (unadjusted/adjusted) at the last follow-up interval. The side effects are listed in Tables 2 and 3 . A statistical analysis of differences concerning the changes in double vision between the carbon-ion and proton groups was performed. Eight patients who underwent proton radiotherapy and 22 patients who underwent carbon-ion therapy with changes in double vision could be identified and evaluated. No statistically significant difference between the 2 groups could be determined (P 5 .866; Fig. 7) . No treatment-associated secondary malignancies were observed during the follow-up.
DISCUSSION
Results in Comparison With Previously Published Results for Carbon-Ion, Proton, and Photon Irradiation
This is the first study to retrospectively compare the results of proton and carbon-ion treatments for skull base chondrosarcomas at a single center. Because of the rarity of chondrosarcomas, all the evidence for treatment is Original Article currently based on retrospective data. Although the disadvantages of retrospective data are known, these data are the only possibility for comparing the 2 treatment modalities because prospective studies are still recruiting at the moment.
Because of the rareness of chondrosarcomas, the sample size was rather small. Furthermore, the distribution between proton therapy and carbon-ion therapy (22 patients vs 79 patients) and the median time of follow-up (30.7 months for protons and 43.7 months for carbon ions) were not equal. Thus, a statistically significant difference between the 2 irradiation modalities could not be found. A prospective randomized phase 3 study is currently recruiting patients at the HIT (ClinicalTrials.gov identifier NCT01182753) to test for the noninferiority of carbon-ion treatment versus proton treatment in patients with skull base chondrosarcomas.
A previously published study by Uhl et al 8 that presented results of carbon-ion therapy for skull base chondrosarcomas at the GSI Helmholtz Centre for Heavy Ion Research (Darmstadt, Germany) showed 3-, 5, and 7-year LC rates of 95.9%, 88%, and 88%, respectively. In comparison, the results of the prevailing study in a clinical setting, with LC rates at 1, 2, and 4 years of 98.6%, 97.2%, and 90.5%, respectively, seem to be in line with the previously published results.
As for the standard of care, function-preserving surgery combined with additive irradiation, a systematic meta-analysis of 560 patients with intracranial chondrosarcoma by Bloch et al 5 demonstrated 5-year recurrence rates of 44% after surgery alone and 9% after surgery combined with irradiation. In the current study, we were able to show 4-year recurrence rates of 0% for the treatment with protons and 9.3% for the treatment with carbon ions.
Even though high neurological complication rates of up to 33% have been described with the surgical management of skull base chondrosarcomas, 11 biopsying for histological confirmation of the diagnosis is needed, and brainstem compression and tumor volume at the start of irradiation are seen as prognostic factors 8, 12, 13 ; this is the reason that surgery should be performed first. As for the tumor volume, no significant difference between a clinical target volume 36.6 cm 3 and a clinical target volume > 36.6 cm 3 could be seen in the current study for the carbon-ion group.
Kano et al 14 analyzed the use of the Gamma Knife in the irradiation of skull base chondrosarcomas. With a median tumor volume of 8 cm 3 , a median margin dose of 15 Gy, and a median follow-up of 75 months, the LC rates at 3, 5, and 10 years were 88%, 85%, and 70%, respectively. Even though the follow-up was much longer than that in the current study, the results seemed to be inferior to the results of the current study. Compared with the results of other institutions that used particle therapy (as discussed later), the results seemed to be inferior as well.
As for proton therapy for chondrosarcomas, promising results were published earlier. Five-and 10-year LC rates of 98% and 94%, respectively, were described by Munzenrider et al. 15 In their study, 229 patients with low-grade chondrosarcomas (G1) were irradiated with a median dose of 72 Gy (RBE). Feuvret et al 16 analyzed a group of 159 patients who were irradiated after surgery either with protons alone or with a combination of protons and photons with a median dose of 70.2 Gy (RBE). The 5-and 10-year LC rates were 96.4% and 93.5%, respectively. Ares et al 12 published long-term results of proton therapy for 22 patients with skull base chondrosarcomas and reported a 5-year LC rate of 94%. A 5-year LC rate of 92% for 25 patients after proton therapy with a median dose of 71 Gy (RBE) was published by Hug et al. 13 A recent study by Weber et al 17 showed an estimated 7-year LC rate for chondrosarcomas treated with pencil-beam proton therapy after surgery of 93.6% with a mean follow-up of 50 months. An overview can be found in Table 4 .
No significant difference could be found between carbon ions and protons in our trial. Nevertheless, there were no relapses in the subgroup that was treated with protons. A possible explanation could be the shorter follow-up interval of 30.7 months in the proton subgroup versus 43.7 months in the carbon-ion group. With a median time of 29.8 months between therapy and progression in the carbon-ion group, there is a possibility that relapses in the proton group have not been detected yet because of the shorter follow-up interval. Furthermore, the proton-therapy subgroup was considerably smaller than the carbon-ion subgroup. Thus, the determination of a statistically significant difference was not possible.
When it comes to the dose and fractionation differences between the 2 groups, it must be mentioned that the a/b value for chondrosarcomas is not exactly known for the linear-quadratic model. Therefore, the range of the applied doses in the carbon-ion group with a fraction dose of 3 Gy (RBE) was between 65 and 75 Gy (equivalent photon dose, 2 Gy/fraction) with an a/b value ranging from 2 to 10 Gy, even though the second value seems rather unlikely. When we take that into account, there is the possibility that the carbon-ion group received a higher or lower dose than the proton group, which received a fraction dose of 2 Gy (RBE). In addition, there are still uncertainties regarding the accuracy of the used model (a local effect model). 18 Nevertheless, hypofractionation is the standard of care at all centers worldwide that are providing heavy-ion therapy.
In comparison with the proton results from other institutions, the results of the current study concerning carbon ions as well as protons are more or less equal (carbon ions) or even better (protons). What needs to be considered is the fact that the follow-up with a median of 39.5 months was rather short in comparison with the follow-up of the aforementioned studies. In comparison with the previously published data from our institution by Schulz-Ertner et al 19 with a 3-year LC rate of 96.2% and by Uhl et al 8 with 3-, 5-, and 7-year LC rates of 95.9%, 88%, and 88%, respectively, the results are comparable. Nevertheless, the retrospective character of the current study with possible confounders such as the differences in patient numbers and follow-up times has to be taken into account when we are interpreting the results.
Toxicity
A retrospective analysis of the side effects was performed, and it showed mild acute toxicities from the treatment of skull base chondrosarcomas with carbon ions and protons.
Acute side effects
In the first year after irradiation, common side effects such as erythema, mucositis, and alopecia occurred in up to 54% (erythema) of the patients. In the following years, the rates of those symptoms decreased continuously to less than 6% in the unadjusted group.
Hearing A hearing restriction was described in approximately 30% of the patients at the beginning of the irradiation. During the follow-up, an acute worsening could be determined with a peak of 46% for carbon ions and a peak of 68% for protons (each in the unadjusted group). This worsening can be explained by the occurrence of a middle ear effusion, which can be treated with a tympanostomy tube. The corresponding rates were rather stable at the last follow-up interval. Neuropathy is a possible explanation because nerve-sparing irradiation was often not possible. Because of the relatively short follow-up, possible late toxicities may not have been detected yet.
Cranial nerves
The rates of cranial nerve injuries after proton therapy were reported to be 1% at 60 Gy (RBE) and 5% at 70 Gy (RBE) by Urie et al, 20 which mostly occurred within the first 24 months after treatment. In the current analysis, 71% of the patients in the carbon-ion subgroup and 59% in the proton subgroup reported cranial nerve deficits at the start of the irradiation. There was a small increase to 63.6% in the proton subgroup during the first year. After that, there was a continuous decrease to a rate of 33.3% (adjusted) at 3 to 5 years. In the carbon-ion subgroup, there was a gradual decrease from the beginning to a rate of 19.1% (adjusted) at 3 to 5 years. That trend can be explained by an initial increase in the tumor volume due to swelling, which was followed by a reduction in the tumor volume as a result of the irradiation. 
